DeDora Capital’s GSK GSK Stock Holding History

DeDora Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-380	Closed	-$21K	–	220
2022 Q1	$21K	Buy	+380	New	+$20.6K	0.01%	233

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

DeDora Capital's GSK Position: Q2 2022 in Review

DeDora Capital sold out of GSK (GSK) in Q2 2022, closing a stake of 380 shares — an estimated $21K sold.

DeDora Capital first reported a position in GSK in Q1 2022 and held it in 1 quarter. The position peaked at $21K in Q1 2022. 900 funds tracked by Wall St. Rank hold GSK as of Q2 2022.

DeDora Capital reported no remaining GSK position as of Q2 2022 after selling out during the quarter.
DeDora Capital sold 380 GSK shares in Q2 2022, an estimated $21K.
DeDora Capital first reported a position in GSK in Q1 2022 and held it in 1 quarter.
DeDora Capital's GSK position peaked at $21K in Q1 2022.
900 funds tracked by Wall St. Rank held GSK as of Q2 2022.

Based on DeDora Capital's 13F filing for Q2 2022, filed 27 Jul 2022.